BioPorto Publishes 2021 Annual Report
April 06, 2022 04:27 ET
|
BioPorto A/S
April 6, 2022Announcement no. 7 BioPorto Publishes 2021 Annual Report BioPorto A/S (BioPorto), an in vitro diagnostics company focused on saving lives and improving the quality of life with...
Managers’ transactions
April 01, 2022 01:35 ET
|
BioPorto A/S
April 1, 2022Announcement no. 6 Managers’ transactions In connection with the completion of BioPorto A/S’ rights issue as described in company announcement no. 4, BioPorto A/S has received...
Major Shareholder Announcement
April 01, 2022 01:25 ET
|
BioPorto A/S
April 1, 2022Announcement no. 5 Major Shareholder Announcement BioPorto A/S hereby announces the receipt of a notification pursuant to section 38(1) of the Danish Capital Markets Act from...
BioPorto A/S announces completion of rights issue; capital raised, total number of shares, and voting rights
April 01, 2022 01:15 ET
|
BioPorto A/S
April 1, 2022Announcement no. 4 This announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in or into the United States,...
BioPorto A/S announces results of rights issue – Offering fully subscribed
March 28, 2022 06:11 ET
|
BioPorto A/S
March 28, 2022Announcement no. 3 This announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in or into the United States, Canada,...
BioPorto A/S publishes prospectus in connection with a rights issue with pre-emptive subscription rights for its existing shareholders
March 07, 2022 09:23 ET
|
BioPorto A/S
March 7, 2022Announcement no. 2 This announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in or into the United States, Canada,...
BioPorto announces intention to initiate a rights issue with expected gross proceeds of up to approximately DKK 100.4M, updates on status of The NGAL Test clinical trials, and announces its financial estimate for 2021 and guidance for 2022,
March 07, 2022 09:00 ET
|
BioPorto A/S
March 7, 2022Announcement no. 1 BioPorto announces intention to initiate a rights issue with expected gross proceeds of up to approximately DKK 100.4M, updates on status of The NGAL Test clinical...
Grant of warrants
December 31, 2021 11:06 ET
|
BioPorto A/S
December 31, 2021Announcement no. 24Grant of warrants Today, the Board of Directors of BioPorto A/S (“BioPorto”) (Nasdaq: BIOPOR) has exercised its current authorization by issuing 12,600,000...
Pipeline Update on gRAD Tests
December 31, 2021 06:50 ET
|
BioPorto A/S
December 31, 2021News release Pipeline Update on gRAD Tests BioPorto A/S (BioPorto) is supporting Rigshospitalet (RH), Copenhagen, with quantitative thrombomodulin tests based on its generic Rapid...
In an effort to prioritize Emergency Use Authorizations (EUA), the FDA does not recommend that BioPorto pursue an EUA for its NGAL assay for the prediction of renal replacement therapy in COVID-19 patients
November 19, 2021 11:05 ET
|
BioPorto A/S
November 19, 2021Announcement no. 23 In an effort to prioritize Emergency Use Authorizations (EUA), the FDA does not recommend that BioPorto pursue an EUA for its NGAL assay for the prediction of...